SCHEMBL210753

SCHEMBL210753

COC(=O)c1ccc(CNc2nccc(Cl)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
CA1 P00915 3/20 0.51
CA2 P00918 3/20 0.51
DRD2 P14416 1/20 0.48
TBXA2R P21731 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
CLK1 P49759 1/20 0.46
CLK2 P49760 1/20 0.46
DYRK1A Q13627 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
VNN1 O95497 3/20 0.45
LOXL2 Q9Y4K0 1/20 0.45
CNR1 P21554 1/20 0.44
ROCK1 Q13464 1/20 0.44
YTHDC1 Q96MU7 1/20 0.44
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10272800 0.84 CA1 (0.51) ALDH1A1CA1CA2DRD2TBXA2R
SCHEMBL1064735 0.83 CA1 (0.60) ALDH1A1CA1CA2NPC1RAB9A
SCHEMBL210701 0.83 CLK4 (0.50) ALDH1A1CA1CA2DRD2TBXA2R
SCHEMBL14424237 0.82 CA1 (0.49) ALDH1A1CA1CA2DRD2TBXA2R
SCHEMBL13502761 0.81 AURKA (0.62) ALDH1A1NPC1RAB9AROCK1
SCHEMBL12362922 0.80 CLK4 (0.67) CLK1CLK2DYRK1ACLK4DYRK1B
SCHEMBL1063561 0.80 CA1 (0.56) ALDH1A1CA1CA2DRD2TBXA2R
SCHEMBL10272801 0.77 CA1 (0.50) ALDH1A1CA1CA2DRD2TBXA2R
SCHEMBL1065202 0.77 HDAC3 (0.74) DYRK1ACLK4DYRK1B
SCHEMBL28652347 0.76 TP53 (0.60) ALDH1A1DRD2TBXA2RNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 ALDH1A1 680/4885CA1 2297/4885CA2 1511/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 ALDH1A1 758/4885CA1 2424/4885CA2 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.